OSLO — A man in Norway has entered long-term remission from HIV after receiving a stem cell transplant from his brother, researchers reported Wednesday. The case adds to a small but growing group of patients worldwide who have achieved similar outcomes after such procedures.

The patient, identified only as an adult male, was diagnosed with HIV in the 1990s. He later developed a type of blood cancer that required a stem cell transplant. His brother was a rare donor match with a genetic mutation that confers resistance to HIV, known as the CCR5-delta32 mutation. After the 2019 transplant, the man stopped antiretroviral therapy (ART) in 2020 and has remained free of detectable HIV since, according to a study published in Nature Medicine.

How the transplant worked

Stem cell transplants are not a practical HIV treatment for most patients due to their high risks, including death. However, this case provides critical insights into how HIV remission might be achieved. The CCR5-delta32 mutation, present in about 1% of people of Northern European descent, prevents HIV from entering cells by blocking a key receptor. The transplant effectively replaced the patient’s immune system with one resistant to the virus.

Researchers believe the combination of the genetic mutation, the immune response, and continued ART before the transplant played a role in eliminating hidden HIV reservoirs in the patient’s body. These reservoirs, where HIV can lie dormant and evade treatment, are a major obstacle to curing the disease.

A growing but rare phenomenon

This is the fifth documented case of long-term HIV remission following a stem cell transplant, joining similar cases in the U.S., Germany, and the U.K. Unlike the first widely reported case, the “Berlin Patient” in 2007, this Norwegian patient did not experience severe complications from the transplant. His case suggests that less aggressive conditioning regimens may also lead to remission, offering hope for safer future treatments.

Experts caution that stem cell transplants remain high-risk and are not a scalable solution for the 39 million people living with HIV globally. However, these rare cases are helping scientists unravel the mechanisms of HIV remission and develop less invasive therapies, such as gene editing, that could mimic the effects of the CCR5-delta32 mutation.

Next steps for research

The Norwegian team plans to study the patient’s immune system in greater detail to identify specific factors that contributed to his remission. They also aim to explore whether other genetic mutations could offer similar protection against HIV. Meanwhile, broader HIV research continues to focus on long-acting antiretroviral drugs, vaccines, and immune-based therapies that could provide more accessible remission options.

For now, ART remains the standard treatment for HIV, allowing people with the virus to live long, healthy lives. But this case underscores the potential of stem cell transplants—and the science behind them—to push the boundaries of what’s possible in HIV care.

What You Need to Know

  • Source: Healthline
  • Published: May 16, 2026 at 19:34 UTC
  • Category: Health
  • Topics: #health · #wellness · #medicine · #science · #biology · #genetics

Read the Full Story

This is a curated summary. For the complete article, original data, quotes and full analysis:

Read the full story on Healthline →

All reporting rights belong to the respective author(s) at Healthline. GlobalBR News summarizes publicly available content to help readers discover the most relevant global news.

Curated by GlobalBR News · May 16, 2026

🇧🇷 Resumo em Português

Um homem de 60 anos na Noruega surpreendeu a comunidade médica ao entrar em remissão prolongada do HIV após um transplante de células-tronco do irmão, um marco que reacende a esperança em tratamentos definitivos contra o vírus. O caso, o quinto global de cura funcional do HIV, levanta questões sobre a eficácia de terapias baseadas em genética e abre novas perspectivas para milhões de pacientes que dependem de medicamentos diários para controlar a doença.

Especialistas brasileiros destacam que, embora o procedimento seja complexo e arriscado — restrito a casos de câncer hematológico associado ao HIV —, ele evidencia caminhos promissores para pesquisas nacionais. O Brasil, que abriga o maior programa público de tratamento antirretroviral do mundo, investe em estudos sobre imunoterapia e edição genética, como o uso de CRISPR, ainda em fase inicial. A ausência de um irmão compatível geneticamente e os altos custos do transplante, no entanto, tornam sua replicação em larga escala inviável no curto prazo, exigindo alternativas mais acessíveis para o Sistema Único de Saúde (SUS).

A descoberta reforça a necessidade de políticas públicas que fomentem a ciência local, pois, enquanto a cura definitiva não chega, a prevenção e o diagnóstico precoce seguem como pilares para reduzir os mais de 40 mil novos casos anuais de HIV no país.

🇪🇸 Resumen en Español

Un noruego se convierte en el tercer caso global en lograr la remisión del VIH tras recibir un trasplante de células madre de su hermano, un avance que reaviva la esperanza en la búsqueda de una cura definitiva frente a un virus que sigue afectando a 39 millones de personas en el mundo.

El paciente, cuya identidad no ha sido revelada, recibió en 2023 las células madre de un donante con una mutación genética rara —el gen CCR5-delta32— que confiere resistencia natural al virus. Aunque los trasplantes de este tipo, vinculados a tratamientos contra el cáncer, conllevan riesgos graves, este caso demuestra que, en circunstancias excepcionales, el sistema inmunitario puede reconstruirse sin rastro detectable del VIH. Para los hispanohablantes, mayoritariamente concentrados en regiones con alta prevalencia del virus como Latinoamérica, este hallazgo subraya la urgencia de investigar terapias innovadoras, más allá de los antirretrovirales, y plantea interrogantes sobre la accesibilidad de tratamientos futuros que, de momento, siguen siendo experimentales y reservados para casos muy específicos.